These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26252371)

  • 1. Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.
    Toyota Y; Iwama H; Kato K; Tani J; Katsura A; Miyata M; Fujiwara S; Fujita K; Sakamoto T; Fujimori T; Okura R; Kobayashi K; Tadokoro T; Mimura S; Nomura T; Miyoshi H; Morishita A; Kamada H; Yoneyama H; Okano K; Suzuki Y; Masaki T
    Int J Oncol; 2015 Oct; 47(4):1293-302. PubMed ID: 26252371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
    Okamoto K; Miyoshi K; Murawaki Y
    PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest.
    Samukawa E; Fujihara S; Oura K; Iwama H; Yamana Y; Tadokoro T; Chiyo T; Kobayashi K; Morishita A; Nakahara M; Kobara H; Mori H; Okano K; Suzuki Y; Himoto T; Masaki T
    Int J Oncol; 2017 Dec; 51(6):1674-1684. PubMed ID: 29075786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
    Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
    Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo.
    Shi T; Gong J; Fujita K; Nishiyama N; Iwama H; Liu S; Nakahara M; Yoneyama H; Morishita A; Nonura T; Kobara H; Okano K; Suzuki Y; Masaki T
    Int J Oncol; 2021 Feb; 58(2):199-210. PubMed ID: 33491760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.
    Meng F; Henson R; Lang M; Wehbe H; Maheshwari S; Mendell JT; Jiang J; Schmittgen TD; Patel T
    Gastroenterology; 2006 Jun; 130(7):2113-29. PubMed ID: 16762633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
    Zhu HQ; Ma JB; Song X; Gao HJ; Ma CQ; Chang H; Li HG; Liu FF; Lu J; Zhou X
    Oncol Rep; 2016 Dec; 36(6):3488-3496. PubMed ID: 27779693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of gemcitabine and pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3 and PANC-1 in vitro].
    Zhu ZX; Zhang WM; Jia G; Zhou J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):149-52. PubMed ID: 20118008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells.
    Strouch MJ; Milam BM; Melstrom LG; McGill JJ; Salabat MR; Ujiki MB; Ding XZ; Bentrem DJ
    Pancreas; 2009 May; 38(4):409-15. PubMed ID: 19142175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
    Quintavalle C; Burmeister K; Piscuoglio S; Quagliata L; Karamitopoulou E; Sepe R; Fusco A; Terracciano LM; Andersen JB; Pallante P; Matter MS
    Mol Carcinog; 2017 Sep; 56(9):2146-2157. PubMed ID: 28467612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.
    Ou YQ; Zhu Wb; Li Y; Qiu PX; Huang YJ; Xie J; He SM; Zheng XK; Leng TD; Xu D; Yan GM
    Acta Pharmacol Sin; 2010 Jan; 31(1):73-80. PubMed ID: 19966835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
    Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V
    World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation.
    Huyen NT; Prachayasittikul V; Chan-On W
    J Hepatobiliary Pancreat Sci; 2016 Jul; 23(7):397-405. PubMed ID: 27107220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.